Live: One Dial-in One Attendee
Corporate Live: Any number of participants
Recorded: Access recorded version, only for one participant unlimited viewing for 6 months ( Access information will be emailed 24 hours after the completion of live webinar)
Corporate Recorded: Access recorded version, Any number of participants unlimited viewing for 6 months ( Access information will be emailed 24 hours after the completion of live webinar)
The artificial intelligence technologies granted FDA marketing authorization and cleared by the Agency are generally called “locked” algorithms that don’t continually adapt or learn every time the algorithm is used.
However, the FDA is now focusing on those capable of true AI, - machine learning algorithms that continually evolve, often called “adaptive” or “continuously learning” algorithms. Adaptive algorithms can learn from new user data presented to the algorithm through real-world use. The FDA is allowing modifications to algorithms to be made from real-world learning and adaptation, while still ensuring safety and effectiveness of the software as a medical device (SaMD) is maintained, without requiring frequent updates or submissions.
This webinar will discuss information specific to devices that include artificial intelligence algorithms that make real-world modifications that the Agency would require for premarket review. They include the algorithm’s performance, the added concerns for AI / ML software Verification and Validation, the manufacturer’s plan for modifications and the ability of the manufacturer to manage and control risks of the modifications, including the software’s "predetermined change control plan" (PCCP). It will also address using AI to assist in preparing the 510(k) submission documentation for such applications.
Why you should Attend:
The US FDA has defined the steps needed for the regulatory framework for the development of safe and effective medical devices that use advanced artificial intelligence / machine learning algorithms. Artificial intelligence algorithms are software that can learn from and act on data.
The authorization of these technologies was a harbinger of progress that the FDA expects to see as more medical devices incorporate advanced artificial intelligence algorithms to improve their performance and safety. Since AI changes over time, how will the Agency control these changes without requiring newmarketing submissions. AI software validation has some new requirements as well. Industry can use AI to safely speed up the preparation and documentation of company product 510(k) submissions to the Agency as well, which will also be considered in this webinar.
Areas Covered in Session:
Subscribe for Compliance Alerts Research Reports Absolutely Free